Furthermore, although this mutation had been reported in one NSCLC patient, one papillary thyroid carcinoma patient, and one melanoma patient, no data existed on whether this mutation contributed to BRAF activation or showed response to dabrafenib plus trametinib.1, 11, 12. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.